Photodynamic therapy

SciBase strengthens US team with experienced Dermatology executive

Retrieved on: 
Monday, September 4, 2023
Acceleration, Skin, Senior, PDT, Market access, Medicare, Photodynamic therapy, Commercial Operating System, FDA, Macs, Pharmaceutical industry, Dermatology

Dan was previously Senior Director Commercial Insights, Market Access and Field Reimbursement at Biofrontera Inc., a company focused on the Dermatology market treating actinic keratosis with PDT (Photodynamic Therapy).

Key Points: 
  • Dan was previously Senior Director Commercial Insights, Market Access and Field Reimbursement at Biofrontera Inc., a company focused on the Dermatology market treating actinic keratosis with PDT (Photodynamic Therapy).
  • At Biofrontera Inc., Dan was an instrumental leader in launching the new company in the US market with their first FDA approved drug and device combination product in Dermatology.
  • His experience building winning teams within the US Dermatology market, and deep knowledge of the US medical benefit reimbursement landscape, will be key in driving SciBase US sales and market access activities forward.
  • We welcome Dan to the team and look forward to further acceleration of activities in the US market," says Tord Lendau, Chairman of the Board at SciBase.

SciBase strengthens US team with experienced Dermatology executive

Retrieved on: 
Monday, September 4, 2023
Acceleration, Skin, Senior, PDT, Market access, Medicare, Photodynamic therapy, Commercial Operating System, FDA, Macs, Pharmaceutical industry, Dermatology

Dan was previously Senior Director Commercial Insights, Market Access and Field Reimbursement at Biofrontera Inc., a company focused on the Dermatology market treating actinic keratosis with PDT (Photodynamic Therapy).

Key Points: 
  • Dan was previously Senior Director Commercial Insights, Market Access and Field Reimbursement at Biofrontera Inc., a company focused on the Dermatology market treating actinic keratosis with PDT (Photodynamic Therapy).
  • At Biofrontera Inc., Dan was an instrumental leader in launching the new company in the US market with their first FDA approved drug and device combination product in Dermatology.
  • His experience building winning teams within the US Dermatology market, and deep knowledge of the US medical benefit reimbursement landscape, will be key in driving SciBase US sales and market access activities forward.
  • We welcome Dan to the team and look forward to further acceleration of activities in the US market," says Tord Lendau, Chairman of the Board at SciBase.

International Photodynamic Association Announces 2023 Award Recipients in Tampere, Finland

Retrieved on: 
Monday, July 17, 2023
Science, Biotechnology, Research, Oncology, Health, Medical Devices, Infectious Diseases, Clinical Trials, Radium, Faculty, Infection, UCL, PIT, University, PD, PDT, PDD, Government, MICHAEL, McMaster Faculty of Health Sciences, IPA, Congress, Student, Outline of health sciences, University of Johannesburg, Diagnosis, Hospital, Photodynamic therapy, Institute for Cancer Research, Pharmaceutical industry, Forestry

The IPA World Congress featured research on a number of areas that use light-activated photosensitizers, including photodynamic therapy (PDT), antimicrobial photodisinfection, photoimmunotherapy (PIT), photodiagnosis (PD), etc.

Key Points: 
  • The IPA World Congress featured research on a number of areas that use light-activated photosensitizers, including photodynamic therapy (PDT), antimicrobial photodisinfection, photoimmunotherapy (PIT), photodiagnosis (PD), etc.
  • The International Photodynamic Association (IPA) was founded in 1986 to support and endorse the scientific advancement and clinical development of photomedicine, in particular in the areas of photodynamic disinfection, photodynamic therapy (PDT), photoimmunotherapy (PIT), and photodiagnosis (PD).
  • For more information, please go to the site: International Photodynamic Association (IPA)
    The Biennial International Photodynamic Association World Congress aims to bring together researchers and clinicians in all fields of Photodynamic Therapy (PDT) and Photodiagnosis (PDD) since 1986.
  • The 18th IPA World Congress will be held in Tampere, Finland , July 10-15, 2023.

Ondine Biomedical is Recipient of the TAYYABA HASAN IMPACT AWARD at 18th IPA World Congress, Finland

Retrieved on: 
Monday, July 17, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Medical Devices, Infectious Diseases, UCL, PIT, PD, SARS-CoV-2, Infection, PDT, Visual Studio Lab Management, IPA, Congress, Biomedicine, Tayyaba Hasan, ISCB Senior Scientist Award, Photodynamic therapy, Pharmaceutical industry

Ondine Biomedical was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association (IPA) in Tampere, Finland for demonstrating exceptional perseverance and clinical acumen.

Key Points: 
  • Ondine Biomedical was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association (IPA) in Tampere, Finland for demonstrating exceptional perseverance and clinical acumen.
  • Ondine has demonstrated successful outcomes in a number of key studies for both prevention and treatment against strains of SARS-CoV-2 including deployment in large scale enterprises.
  • The IPA promotes the benefits of light-activated therapies to treat infections that pose the biggest threats to global health security.
  • The IPA wishes to congratulate the Ondine team for being recognized as the 2023 recipient of the Tayyaba Hasan IMPACT Award.

International Photodynamic Association: Global Experts Gather in Finland to Discuss Advances in Photomedicine – a Leading Alternative to Antibiotics in the Battle Against AMR

Retrieved on: 
Thursday, July 6, 2023
Medical Devices, Health, Health Technology, Research, Science, Biotechnology, Dentistry, Infection, Gold medal, Harvard–MIT Program in Health Sciences and Technology, University, PIT, PD, Life, World Congress, Sleep hygiene, PDT, PDD, Attention, AMR, Cutaneous leishmaniasis, Fungus, Doctor of Philosophy, Harvard Medical School, University of Coimbra, IPA, Congress, Hospital, Sinusitis, Patient, Outline of health sciences, Diagnosis, Fungal infection, Photodynamic therapy, Bacteria, HMS, Virus, Skin, Vaccine, Pharmaceutical industry, Dermatology, Chemistry

APDT has not only proven to be effective against all types of pathogens but does not generate resistance or serious adverse effects unlike antibiotics.

Key Points: 
  • APDT has not only proven to be effective against all types of pathogens but does not generate resistance or serious adverse effects unlike antibiotics.
  • There are a growing number of applications for aPDT that are being developed in leading research centres around the world.
  • It is gratifying to see the quality of research and commercial applications being showcased at this World Congress.
  • The Biennial International Photodynamic Association World Congress aims to bring together researchers and clinicians in all fields of Photodynamic Therapy (PDT) and Photodiagnosis (PDD) since 1986.

Photonamic and Lumeda Enter into Collaboration for a Clinical Study with Photodynamic Therapy ("PDT") in the Field of Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Thursday, February 16, 2023
PDT, Gesellschaft mit beschränkter Haftung, Immunotherapy, Ix, Safety, Patient, Clinical trial, Lung cancer, Immune system, Photodynamic therapy, ICIS, Cancer, Pharmaceutical industry, Medical imaging

ROCKY HILL, Conn. and PINNEBERG, Germany, Feb. 16, 2023 /PRNewswire-PRWeb/ -- Lumeda Inc, a clinical-stage medical technology company focused on improving treatment outcomes of patients with lung cancer, and photonamic GmbH & Co KG, a pharmaceutical company involved in the development of 5-aminolevulinic acid (5-ALA) in various applications as a precursor for the photosensitizer PpIX, today announced their commitment to collaborate on a Phase I-II clinical study to evaluate the safety and efficacy of Photodynamic Therapy (PDT) with 5-ALA as an adjuvant in combination with Immune Checkpoint Inhibitors (ICIs) to prime the immune system in the treatment of lung cancer patients. The collaboration will combine the respective expertise of both companies, where photonamic's photosensitizing drug Gleolan™(5-ALA) is used in combination with Lumeda's proprietary DigiLum™ PDT technology, a breakthrough light delivery and dosimetry system. Ulrich Kosciessa, CEO of photonamic said "The photonamic team is excited about the potential for this collaboration to expand the therapeutic indications for Gleolan™, starting with lung cancer."

Key Points: 
  • The collaboration will combine the respective expertise of both companies, where photonamic's photosensitizing drug Gleolan™(5-ALA) is used in combination with Lumeda's proprietary DigiLum™ PDT technology, a breakthrough light delivery and dosimetry system.
  • Ulrich Kosciessa, CEO of photonamic said "The photonamic team is excited about the potential for this collaboration to expand the therapeutic indications for Gleolan™, starting with lung cancer."
  • This combination study using Gleolan™ and DigiLum™ seeks to assess the response of patients with late-stage lung cancer.
  • Lung cancer is one type of cancer for which PDT has demonstrated the potential to offer clinical benefits.

Data presented at the International Bladder Cancer Network (IBCN) meeting demonstrate a reduction in the risk of recurrence with the use of BLC

Retrieved on: 
Tuesday, October 4, 2022
PDT, Association, BLC, African Americans, Photocure, Survival, Industry, Photodynamic therapy, VA, PDD, Recurrence, ASA, WLC, Patient, Time, Overalls, Diagnosis, Bladder cancer, Cystoscopy, NMIBC, University, Impact, Access, University of Texas Medical Branch, Medical imaging

The IBCN meeting brings together international Bladder Cancer Experts and scientists, with the mission to improve the diagnosis, prevention, and treatment of bladder cancer.

Key Points: 
  • The IBCN meeting brings together international Bladder Cancer Experts and scientists, with the mission to improve the diagnosis, prevention, and treatment of bladder cancer.
  • A significant decrease in risk of recurrence following BLC utilization compared to WLC alone (HR, 0.70, p=0.005) was also determined.
  • Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall.NMIBC remains in the inner layer of cells lining the bladder.
  • Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients.

Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol

Retrieved on: 
Thursday, December 2, 2021
Patent, Photodynamic therapy, BFRI, Private Securities Litigation Reform Act, Face, Company, United States Patent and Trademark Office, LSA, SEC, DUSA Pharmaceuticals, Scalp, COVID-19, Nociception, Dermatology, BF, Nasdaq, GLOBE, Health, Impetigo, Marketing, PDT, FDA, XL, USPTO, Pharmaceutical industry, Medical imaging

This patented illumination protocol demonstrates Biofronteras commitment to the patients need for innovative treatments.

Key Points: 
  • This patented illumination protocol demonstrates Biofronteras commitment to the patients need for innovative treatments.
  • The patent application claims a method for photodynamic therapy in which a dynamic and innovative illumination protocol is implemented.
  • This protocol consists of changing illumination intensities combined in a predefined order with interruptions of the illumination to specifically modulate and reduce pain perception to the patient.
  • Implementation of the protocol to Biofronteras medical devices requires a software installation and can be rolled-out to both the BF-RhodoLED and BF-RhodoLED XL lamps.

Lumeda Announces Appointment of Jason Pesterfield to Board of Directors

Retrieved on: 
Tuesday, July 20, 2021
Health sciences, Medicine, Clinical medicine, Cancer treatments, Adjuvants, Pulmonology, Photodynamic therapy, Adjuvant therapy, Surgical oncology, Therapy

ROCKY HILL, Conn., July 20, 2021 /PRNewswire-PRWeb/ -- Lumeda Inc. , a medical technology company advancing Photodynamic Therapy (PDT) as an intraoperative adjuvant treatment for patients during lung cancer surgery, today announced the appointment of Jason Pesterfield to its board of directors.

Key Points: 
  • ROCKY HILL, Conn., July 20, 2021 /PRNewswire-PRWeb/ -- Lumeda Inc. , a medical technology company advancing Photodynamic Therapy (PDT) as an intraoperative adjuvant treatment for patients during lung cancer surgery, today announced the appointment of Jason Pesterfield to its board of directors.
  • "We are excited to have Jason join our board of directors to bring his deep experience in lung cancer surgery and global connections to thoracic surgeons and interventional pulmonologist," said Lumeda CEO, Sandy Zinke.
  • "Jason has significant expertise in developing innovative commercialization strategies to launch new medical technologies in the lung cancer space.
  • "I am excited to be joining the talented Lumeda team to help them introduce this important adjuvant therapy for treating lung cancer," said Pesterfield.

Kintara Therapeutics to Participate at the Benzinga Global Small Cap Conference

Retrieved on: 
Wednesday, May 5, 2021
Health sciences, Life sciences, Applied sciences, Biotechnology, Drug discovery, Health policy, Medicinal chemistry, Therapy, Biopharmaceutical, Photodynamic therapy

b'SAN DIEGO, May 5, 2021 /PRNewswire/ --Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that its Chief Executive Officer Saiid Zarrabian will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nMr.

Key Points: 
  • b'SAN DIEGO, May 5, 2021 /PRNewswire/ --Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that its Chief Executive Officer Saiid Zarrabian will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nMr.
  • Based on Kintara\'s internal research programs and these priorNCI-sponsoredclinical studies, Kintara is currently conducting clinical trials to support the development and commercialization ofVAL-083in GBM.\nREM-001 is a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications.
  • REM-001therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.